In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of BioXcel Therapeutics Inc (NASDAQ: BTAI) was $6.8 for the day, up 6.25% from the previous closing price of $6.4. In other words, the price has increased by $6.25 from its previous closing price. On the day, 35.31 million shares were traded. BTAI stock price reached its highest trading level at $8.08 during the session, while it also had its lowest trading level at $4.8001.
Ratios:
Our analysis of BTAI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.74 and its Current Ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 16 ’24 when O’Neill Vincent sold 165 shares for $0.35 per share. The transaction valued at 58 led to the insider holds 19,957 shares of the business.
Mehta Vimal sold 3,117 shares of BTAI for $1,131 on Dec 16 ’24. The CEO and President now owns 59,605 shares after completing the transaction at $0.36 per share. On Dec 16 ’24, another insider, Steinhart Richard I, who serves as the Chief Financial Officer of the company, sold 577 shares for $0.36 each. As a result, the insider received 207 and left with 20,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 41181140 and an Enterprise Value of 190235856. For the stock, the TTM Price-to-Sale (P/S) ratio is 47.33. Its current Enterprise Value per Revenue stands at 219.166 whereas that against EBITDA is -3.816.
Stock Price History:
The Beta on a monthly basis for BTAI is -0.11, which has changed by -0.37407953 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, BTAI has reached a high of $13.36, while it has fallen to a 52-week low of $1.17. The 50-Day Moving Average of the stock is 221.63%, while the 200-Day Moving Average is calculated to be 72.00%.
Shares Statistics:
BTAI traded an average of 6.39M shares per day over the past three months and 41787470 shares per day over the past ten days. A total of 6.06M shares are outstanding, with a floating share count of 5.49M. Insiders hold about 9.28% of the company’s shares, while institutions hold 6.84% stake in the company. Shares short for BTAI as of 1753920000 were 265503 with a Short Ratio of 0.04, compared to 1751241600 on 336411. Therefore, it implies a Short% of Shares Outstanding of 265503 and a Short% of Float of 4.79.
Earnings Estimates
The stock of BioXcel Therapeutics Inc (BTAI) is currently in the spotlight, with 3.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.99, with high estimates of -$0.63 and low estimates of -$1.68.
Analysts are recommending an EPS of between -$3.21 and -$9.17 for the fiscal current year, implying an average EPS of -$6.15. EPS for the following year is -$4.61, with 4.0 analysts recommending between -$2.02 and -$11.87.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $300k to a low estimate of $200k. As of the current estimate, BioXcel Therapeutics Inc’s year-ago sales were $214kFor the next quarter, 4 analysts are estimating revenue of $352.5k. There is a high estimate of $460k for the next quarter, whereas the lowest estimate is $200k.
A total of 5 analysts have provided revenue estimates for BTAI’s current fiscal year. The highest revenue estimate was $2.35M, while the lowest revenue estimate was $700k, resulting in an average revenue estimate of $1.24M. In the same quarter a year ago, actual revenue was $2.27MBased on 5 analysts’ estimates, the company’s revenue will be $4.76M in the next fiscal year. The high estimate is $10.15M and the low estimate is $700k.
